Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Detalles Bibliográficos
Autores principales: Martinez-Lopez, J, Sanchez-Vega, B, Barrio, S, Cuenca, I, Ruiz-Heredia, Y, Alonso, R, Rapado, I, Marin, C, Cedena, M-T, Paiva, B, Puig, N, Mateos, M-V, Ayala, R, Hernández, M-T, Jimenez, C, Rosiñol, L, Martínez, R, Teruel, A-I, Gutiérrez, N, Martin-Ramos, M-L, Oriol, A, Bargay, J, Bladé, J, San-Miguel, J, Garcia-Sanz, R, Lahuerta, J-J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467041/
https://www.ncbi.nlm.nih.gov/pubmed/28210002
http://dx.doi.org/10.1038/leu.2017.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467041/
https://www.ncbi.nlm.nih.gov/pubmed/28210002
http://dx.doi.org/10.1038/leu.2017.58

Ejemplares similares